Why the study?
Does gemfibrozil improve lipid and coagulation profiles in hyperlipidaemic patients with stable peripheral arterial occlusive disease?
Does gemfibrozil improve lipid and coagulation profiles in hyperlipidaemic patients with stable peripheral arterial occlusive disease?
Gemfibrozil effectively improves lipid profiles in patients with peripheral arterial disease but may have a potentially adverse effect by increasing plasma fibrinogen levels.
Answers are grounded in this paper and cite their sources.
Gemfibrozil-associated lipid improvements accompanied fibrinogen rise in stable PAOD; hypothesis-generating and should not yet change practice.
The effects of gemfibrozil were assessed in 27 hyperlipidaemic patients with stable peripheral arterial occlusive disease. Gemfibrozil (600 mg twice daily) was administered for 12 weeks after 2 weeks of placebo medication, thus enabling patients to act as their own controls. Serum cholesterol levels were reduced by a mean of 11.3%, triglycerides by 42.3% and low density lipoprotein cholesterol by 19.9%. Small but significant increases in HDL3 and apolipoprotein A-II also occurred. New findings included significant reductions in plasma lipid peroxides and Factor VIIc levels and a mean increase of 19% in antithrombin III concentrations. Furthermore, plasma fibrinogen levels increased by a mean of 17.6%, a potentially adverse effect of gemfibrozil that has not been previously reported.
No takes yet. Share an insight, caveat, or question.
Stringer et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: